Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety
Conclusion: CBD-rich cannabis oil (CBD: THC 20:1), appears to have a good safety profile. Long-term monitoring with a larger number of participants is warranted.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Autism | Bilirubin | Brain | Children | Clinical Trials | Drugs & Pharmacology | Liver | Neurology | Potassium | Study | Thyroid | Urology & Nephrology